Abstract Library

#4637 Non-functional retroperitoneal paraganglioma in a young patient: A case report

Introduction: Paragangliomas are neuroendocrine tumours arising in the parasympathetic nervous system, outside the adrenal gland. Retroperitoneal location is extremely rare. Non-functional paragangliomas often represent a diagnostic challenge.

Conference:

Presenting Author:

Authors: Aris H, Saidi M, Lahfa I,

Keywords: retroperitoneal paraganglioma, surgery, monitoring,

#4608 A complex and rare association of neuroendocrine and endocrine neoplasms: A case report

Introduction: Neuroendocrine tumours (NETs) are sporadic or genetically inherited heterogenous neoplasms affecting multiple sites.

Conference:

Presenting Author: Cerroni L

Authors: Cerroni L, Filice A, Feola T, Sesti F, Vincenzi L,

Keywords: cushing disease, atypical carcinoid, ileal net, genetics,

#4605 Primary mammary neuroendocrine tumour: A case report and literature review

Introduction: Primary neuroendocrine carcinomas of the breast are rare, accounting for only 2 to 5% of all breast cancers. These tumours have recently been included in the latest WHO classification of breast tumours. The diagnosis can be challenging due to its uncommon presentation and overlap with other breast pathologies.

Conference:

Presenting Author:

Authors: Boudersa A, Kouadri N,

Keywords: primary neuroendocrine, breast cancer,

#4577 Diagnosis of a cervical carotid paraganglioma: A case report and review of diagnostic imaging approaches

Introduction: Cervical paragangliomas are rare, often non-secreting tumours of neuroectodermal origin. Their diagnosis can be challenging due to the variability of clinical presentations and the diagnostic tests required.

Conference:

Presenting Author: Otmane R

Authors: Otmane R, Boudersa A, Kouadri N,

Keywords: Paraganglioma, cervical, octreoscan,

#4569 Dramatic response to tarlatamab in a patient with metastatic primary small cell neuroendocrine carcinoma of the breast

Introduction: Primary small cell neuroendocrine carcinoma of the breast (SCNCB) is a rare malignancy with a poor prognosis. Tarlatamab, a DLL3-targeted bispecific T-cell engager, is FDA-approved for extensive-stage small cell lung carcinoma.

Conference:

Presenting Author: Patel D

Authors: Patel D, Alahmadi A, Maddocks K, Lampert B, Giglio P,

Keywords: tarlatamab, small cell neuroendocrine carcinoma of the breast,